Ambros Therapeutics
Last verified 2026-05-05. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $125.0Mattributed |
|---|---|
| Latest round | series-a, $125.0M, 2025-12-01attributed |
| Founded | 2022 |
| Headquarters | Irvine CA |
| Industry | biotech|therapeutics|pain |
| Stage | series-a |
| Website | ambros.bio |
Targeted-protein-degradation biotech building bifunctional small molecules to drug previously-undruggable proteins. Sells to pharma partners and patient populations with currently inaccessible oncology and immunology targets. Focused on novel ligase recruiters that expand the chemical space of protein degraders beyond the standard CRBN and VHL toolkits.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-12-01 | series-a | $125.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $125.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $125.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | ambros.bio, read 2026-05-05 |
| Description | self-reported | ambros.bio, read 2026-05-05 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.